Skip to main content
Clinical Trials/CTRI/2025/06/089561
CTRI/2025/06/089561Not yet recruitingPhase 2/3

Effectiveness of individualized homoeopathic treatment add on to lifestyle modifications in cases of Non-Alcoholic Fatty Liver Disease (NAFLD): A double-blind randomized placebo-controlled trial

Central Council for Research in Homoeopathy4 sites in 1 country400 target enrollmentStarted: August 1, 2025Last updated:

Trial Snapshot

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
Enrollment
400
Locations
4
Primary Endpoint
Qualitative assessment of the liver by ultrasonography:

Study Overview

Brief Summary

Non-alcoholic fatty liver disease is a clinic-histopathological condition characterized by a spectrum of conditions characterized histologically by macrovesicular hepatic steatosis in those who do not consume alcohol in amounts generally considered harmful to the liver. The global prevalence of the disease is approximately 25% of the population and the prevalence of disease in India is approximately 9 – 35%. Obesity, type 2 (non-insulin-dependent) diabetes mellitus, and hyperlipidaemia are coexisting conditions frequently associated with NAFLD. The condition can be found in any age group including in childhood but the highest prevalence has been observed between 40 – 50 years of age. Most of the cases of NAFLD do not produce any signs of liver disease at the time of diagnosis, although symptoms of fatigue or malaise and sensation of discomfort or fulness over the right upper part of the abdomen may be present. An incidental rise in transaminases and fatty liver during ultrasonography conducted during routine check-ups may be the only demonstrable sign of the disease. Ultrasonography has a specificity and sensitivity of 85% in the detection of hepatic steatosis. Biochemical tests usually show mildly elevated AST and ALT, with the latter often higher.  Fibroscan (transient elastography) is another non-invasive procedure that determines the extension of fibrosis within the liver tissue and directly does not relate to the fat content within the liver. Pharmacological interventions for the condition did not offer much conclusive evidence till now as most of the reviews and clinical practice guidelines suggested. The availability of the evidence suggests a very low quality of evidence with a high risk of bias. Certain herbal medicines also demonstrated some positive evidence but again such studies suffered a significantly high risk of bias. No studies have been conducted in Homoeopathy on this condition to date. Moreover, Homoeopathy has also been criticized to be a causative factor behind the development of severe hepatitis due to the vehicle of alcohol being used in Homoeopathic medicines. Therefore a double blind placebo controlled study as an add on to lifestyle modification is being conducted to generate the necessary evidence for the condition. The study shall include patients aged 18 to 75 years of all gender with evidences of fatty changes in liver and shall be prospectively studied to observe changes in the laboratory and imaging parameters to elicit changes in relation to intervention and placebo along with lifestyle modifications.  The study is of 3 years duration, after which the the data shall be subjected to statistical analysis and the findings shall be disseminated to the scientific community for further researches and implementations.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant and Investigator Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 75.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients visiting the OPD of study centers with ultrasonography evidence of fatty changes in the liver on incidental discovery.
  • Fatty liver changes demonstrated by ultrasonography in patients with incidental increase in liver transaminases (ALT and AST)
  • Fatty liver changes demonstrated by ultrasonography in persons screened with either of increased waist circumference (more than 90cm in males and more than 80cm in females), impaired fasting glucose (Fasting glucose more than equal to 110 mg/dl or on pharmacological treatment for impaired glucose), increased blood pressure (more than equal to 130/85 mm of Hg or on antihypertensives), hypertriglyceridemia (Serum triglycerides more than equal to 150mg/dl or on triglyceride or lipid lowering drugs), decreased HDL levels (less than 40 mg/dl in males and less than 50 mg/dl in females).
  • Patients presenting with Grade 1 (mild) or Grade 2 (Moderate) fatty liver on ultrasound examination
  • Patients with transient elastography (FibroScan) Liver Stiffness Measurement scores of less than 9.3kPa (by M probe) and less than 9.6kPa (by XL probe)
  • Patients with FIB 4 score less than equal to 1.45
  • Age 18 to 75 years of age
  • All sexes
  • Patients on oral hypoglycemic drugs, antihypertensives, lipid lowering drugs, and LT4 drugs with controlled disease conditions for which such drugs are administered.
  • Patients with ability to perform and comply to exercise and lifestyle modifications
  • Willing to give consent to participate in the study.

Exclusion Criteria

  • Patients suffering from self-reported cases of liver cirrhosis, hepatocellular carcinoma, hereditary hemochromatosis, Wilson’s disease, alpha 1 antitrypsin deficiency or any other malignancy or any end-stage disease.
  • Patient with positive HbsAg and/or anti HCV antibody.
  • Patients with associated acute or chronic cholecystitis (calculous or acalculous).
  • Patients with such conditions may be included after 6 months of cholecystectomy
  • Drug-induced liver disease
  • Patient with a history of regular alcohol intake demonstrated by CAGE scores of more than equal to 3
  • Patients who are immune-compromised or have steroid medication.
  • Pregnant and lactating mothers
  • Persons with severe Musculoskeletal disorders and unable to perform the prescribed physical activities and exercise.
  • Persons with severe mental illness like mania, insanity.
  • Persons not willing to provide consent for the study.

Outcomes

Primary Outcomes

Qualitative assessment of the liver by ultrasonography:

Time Frame: The scoring shall be done at baseline, 6 months and 12 months.

Secondary Outcomes

  • Quantitative assay of Alanine Aminotransferase (ALT)
  • Liver Stiffness measure score using transient elastography (Fibroscan)
  • Liver fibrosis by Fib 4 scores
  • Quantitative assay of serum triglyceride and high-density lipoprotein cholesterol level
  • Assessment of causality of adverse events using Naranjo ADR probability scale
  • CAP score by fibroscan(The assessment shall be performed at baseline, 6 months and 12 months)

Investigators

Sponsor
Central Council for Research in Homoeopathy
Sponsor Class
Government funding agency
Responsible Party
Principal Investigator
Principal Investigator

Dr Baidurjya Bhattacharjee

Regional Research Institute for Homoeopathy, Siliguri

Study Sites (4)

Loading locations...

Similar Trials